AR125073A1 - USE OF AN OREXIN-2 RECEPTOR AGONIST FOR THE TREATMENT OF AN OREXIN-MEDIATED DISEASE OR DISORDER - Google Patents
USE OF AN OREXIN-2 RECEPTOR AGONIST FOR THE TREATMENT OF AN OREXIN-MEDIATED DISEASE OR DISORDERInfo
- Publication number
- AR125073A1 AR125073A1 ARP220100560A ARP220100560A AR125073A1 AR 125073 A1 AR125073 A1 AR 125073A1 AR P220100560 A ARP220100560 A AR P220100560A AR P220100560 A ARP220100560 A AR P220100560A AR 125073 A1 AR125073 A1 AR 125073A1
- Authority
- AR
- Argentina
- Prior art keywords
- orexin
- methyl
- disorder
- mediated disease
- phenylcyclohexyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se describen en el presente documento 3-((metilsulfonil)amino)-2-(((4-fenilciclohexil)oxi)metil)-piperidin-1-carboxilato de metilo (compuesto (I)), o una de sus sales, hidratos o solvatos farmacéuticamente aceptables, composiciones que comprenden el compuesto (I), y el uso del compuesto (I) para el tratamiento de una enfermedad o trastorno mediados por orexina, tales como hipersomnia idiopática y somnolencia diurna excesiva, en un ser humano que lo necesita. Reivindicación 1: Un método de tratamiento de una enfermedad o trastorno mediados por orexina en un ser humano con niveles normales de orexina que comprende la administración al ser humano de una cantidad terapéuticamente eficaz de (2R,3S)-3-((metilsulfonil)amino)-2-(((cis-4-fenilciclohexil)oxi)metil)piperidin-1-carboxilato de metilo o una de sus sales, hidratos o solvatos farmacéuticamente aceptables, en donde la cantidad terapéuticamente eficaz de (2R,3S)-3-((metilsulfonil)amino)-2-(((cis-4-fenilciclohexil)oxi)metil)piperidin-1-carboxilato de metilo o una de sus sales, hidratos o solvatos farmacéuticamente aceptables aumenta el tiempo de latencia de inicio del sueño más que el placebo.Described herein are methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)-piperidine-1-carboxylate (compound (I)), or a salt thereof, hydrates or pharmaceutically acceptable solvates, compositions comprising compound (I), and the use of compound (I) for the treatment of an orexin-mediated disease or disorder, such as idiopathic hypersomnia and excessive daytime sleepiness, in a human in need thereof . Claim 1: A method of treating an orexin-mediated disease or disorder in a human with normal orexin levels comprising administering to the human a therapeutically effective amount of (2R,3S)-3-((methylsulfonyl)amino methyl )-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein the therapeutically effective amount of (2R,3S)-3 Methyl -((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a pharmaceutically acceptable salt, hydrate or solvate thereof increases sleep onset latency time more than placebo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160423P | 2021-03-12 | 2021-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125073A1 true AR125073A1 (en) | 2023-06-07 |
Family
ID=80820092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100560A AR125073A1 (en) | 2021-03-12 | 2022-03-11 | USE OF AN OREXIN-2 RECEPTOR AGONIST FOR THE TREATMENT OF AN OREXIN-MEDIATED DISEASE OR DISORDER |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR125073A1 (en) |
| TW (1) | TW202302100A (en) |
| WO (1) | WO2022190060A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2214247C (en) | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| EP0929574B1 (en) | 1996-08-27 | 2005-06-29 | Praecis Pharmaceuticals Incorporated | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS |
| AU5773500A (en) | 1999-06-28 | 2001-01-31 | Board Of Trustees Of The University Of Illinois, The | Inhibitors of memapsin 2 and use thereof |
| US10287305B2 (en) | 2016-02-04 | 2019-05-14 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
-
2022
- 2022-03-11 TW TW111109057A patent/TW202302100A/en unknown
- 2022-03-11 AR ARP220100560A patent/AR125073A1/en unknown
- 2022-03-11 WO PCT/IB2022/052214 patent/WO2022190060A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022190060A1 (en) | 2022-09-15 |
| TW202302100A (en) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2800026T3 (en) | Treatment of immune and inflammatory diseases | |
| PE20061163A1 (en) | SUBSTITUTE N-SULFONYLAMINOPHENYLETHYL-2-PHENOXYACETAMIDE COMPOUNDS | |
| PE20211810A1 (en) | NOVEL COMPOUNDS | |
| PE20061150A1 (en) | DERIVATIVES OF N- (N-SULFONYLAMINOARILMETIL) CYCLOPROPANOCARBOXAMIDE SUBSTITUTED AS ANTAGONISTS OF THE VAINILLOID RECEPTOR TYPE 1 (VDR1) | |
| BRPI0515896A (en) | a compound or a pharmaceutically acceptable salt or ester thereof, a method for treating or prophylaxis a host infected with a flavivirus, pestivirus or hepacivirus infection, and a pharmaceutical composition for treating a host infected with a flavivirus, pestivirus or hepacivirus | |
| BR0316082A (en) | Methods of treating or preventing and controlling a myeloproliferative disease, reducing or preventing an adverse effect associated with the administration of a second active agent in a patient suffering from a myeloproliferative disease and enhancing the therapeutic efficacy of a myeloproliferative disease treatment, composition. pharmaceutical and kit | |
| PE20120654A1 (en) | FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-1,3-IL) ISOINDOLIN-1,3-DIONA | |
| ECSP088218A (en) | BENCIMIDAZOLS REPLACED AS CINASA INHIBITORS | |
| PE20070693A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN | |
| PE20151091A1 (en) | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | |
| BRPI0409910A (en) | Methods for the Treatment of Interleukin-6 Related Diseases | |
| DE602005019043D1 (en) | Glucagonone receptor agonists, their preparation and their therapeutic use | |
| PE20051054A1 (en) | HETEROCYCLIC COMPOUNDS USEFUL AS SECRETAGOGS OF GROWTH HORMONE | |
| PE20120668A1 (en) | A COMPOUND N, N-DIMETHYL-5- (2-METHYL-6 - ((5-METHYLPYRAZIN-2-IL) CARBAMOIL) BENZOFURAN-4-ILOXI) PYRIMIDINE-CARBOXAMIDE AS A GLUCKINASE ACTIVATOR | |
| PE20070521A1 (en) | 7- [2- [4- (6-FLUORO-3-METHYL-1,2-BENZYSOXAZOL-5-IL) -1-PIPERAZINYL] ETHYL] -2- (1-PROPINYL) -7H-PIRAZOLE- [4, 3-E] - [1,2,4] -TRIAZOL- [1,5-C] -PYRIMIDIN-5-AMINE AS ANTAGONIST OF THE ADENOSINE A2a RECEPTOR | |
| PT1173197E (en) | METABOLIC INTERVENTION WITH GLP-1, TO IMPROVE THE FUNCTION OF ISCHEMIC AND REPERFUNDED TISSUE | |
| BRPI0809655B8 (en) | use of a compound and a therapeutic agent, pharmaceutical composition, and kit | |
| PE20191557A1 (en) | PIRIMIDINYL-PYRIDYLOXY-NAFTILE COMPOUNDS AND METHODS TO TREAT IRE-RELATED DISEASES AND DISORDERS1 | |
| GEP20115302B (en) | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
| BR112016028819A2 (en) | pharmaceutical composition, methods for treating a disease or condition in a human and for inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, pharmaceutically acceptable salt , isomer or mixture thereof, and use of a compound, pharmaceutically acceptable salt or mixture thereof. | |
| AR048336A1 (en) | HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE | |
| SV2009002900A (en) | DIARILURE FOR THE TREATMENT OF PULMONARY HYPERTENSION | |
| NI201300030A (en) | GPR119 RECEPTOR MODULATORS AND THE TREATMENT OF RELATED DISORDERS | |
| RU2019143573A (en) | COMBINED THERAPY OF NEUROSYCHIATRIC DISORDERS SENSITIVE TO NMDAR ANTAGONIST | |
| AR040248A1 (en) | PHARMACO FOR THE TREATMENT OF HYPERACTIVE BLADDER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |